Eliem Therapeutics Income After Taxes 2021-2024 | CLYM
Eliem Therapeutics income after taxes from 2021 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Eliem Therapeutics Annual Income After Taxes (Millions of US $) |
2023 |
$-35 |
2022 |
$-45 |
2021 |
$-47 |
2020 |
$-21 |
Eliem Therapeutics Quarterly Income After Taxes (Millions of US $) |
2024-06-30 |
$-55 |
2024-03-31 |
$-2 |
2023-12-31 |
$-4 |
2023-09-30 |
$-4 |
2023-06-30 |
$-5 |
2023-03-31 |
$-22 |
2022-12-31 |
$-8 |
2022-09-30 |
$-10 |
2022-06-30 |
$-15 |
2022-03-31 |
$-13 |
2021-12-31 |
$-11 |
2021-09-30 |
$-10 |
2021-06-30 |
$-9 |
2021-03-31 |
$-19 |
2020-12-31 |
|
2020-09-30 |
$-2 |
2020-06-30 |
$-2 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.342B |
$0.000B |
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|